| Market Cap | 821.15K | P/E | 0.00 | EPS this Y | -46.30% | Ern Qtrly Grth | - |
| Income | -124.03M | Forward P/E | 0.00 | EPS next Y | 18.10% | 50D Avg Chg | -5.00% |
| Sales | 37.41M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -98.00% |
| Dividend | N/A | Price/Book | 0.00 | EPS next 5Y | - | 52W High Chg | -100.00% |
| Recommedations | 1.00 | Quick Ratio | 0.63 | Shares Outstanding | 21.06M | 52W Low Chg | 30.00% |
| Insider Own | 1.26% | ROA | -44.17% | Shares Float | 4.03M | Beta | 2.43 |
| Inst Own | 23.55% | ROE | - | Shares Shorted/Prior | 102.04K/117.64K | Price | 0.04 |
| Gross Margin | 0.75% | Profit Margin | - | Avg. Volume | 12,698 | Target Price | 60.00 |
| Oper. Margin | -309.92% | Earnings Date | - | Volume | 8,405 | Change | 0.00% |
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.
